4basebio (LON:4BB) Shares Break Below Two Hundred Day Moving Average – Should You Sell?

4basebio PLC (LON:4BB)’s stock price crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of GBX 522.10 and traded as low as GBX 500. 4basebio shares last traded at GBX 500, with a volume of 45 shares trading hands.

4basebio Stock Performance

The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The firm’s 50-day simple moving average is GBX 524.74 and its two-hundred day simple moving average is GBX 522.10. The stock has a market capitalization of £82.07 million, a PE ratio of -4.57 and a beta of 1.09.

4basebio (LON:4BB) last posted its quarterly earnings data on Monday, September 28th. The company reported GBX (0.57) earnings per share for the quarter. On average, equities research analysts expect that 4basebio PLC will post -3.43 earnings per share for the current fiscal year.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.